Abstract of Durability Study Results for iTind Procedure Presented at 2022 American Urological Association Annual Meeting
CENTER VALLEY, Pa. and HAMBURG, Germany, May 18, 2022 /PRNewswire/ — Olympus, a number one world medtech firm offering revolutionary options for medical and surgical procedures, introduced at this time the abstract outcomes of a follow-up research to measure the sturdiness of the iTind™ process for treating the decrease urinary tract signs brought on by BPH (benign prostatic hyperplasia). The abstract was offered on the American Urological Association Annual Meeting (AUA) on May 15, 2022.1
Study outcomes present the long-term efficacy of the iTind process for IPSS (International Prostate Symptom Score) and QoL (Quality of Life) with sturdiness as much as 6.6 years. Two out of fifty sufferers required subsequent surgical intervention throughout the research interval from 36 to 79 months after preliminary remedy with the iTind process. No late post-operative problems had been reported, and no sufferers returned to BPH medicine.
“Our long-term follow-up with sufferers was hampered by the worldwide pandemic. Still, we had been in a position to report on IPSS, QoL and sturdiness as much as 6.6 years,” mentioned Professor Francesco Porpiglia, MD, Chair of the Urology Division at San Luigi Gonzaga Hospital, University of Turin in Torino, Italy, and first investigator of the research. “The knowledge show that the iTind process is a protected and efficient remedy for BPH signs that’s sturdy over time.”
“These research outcomes are extremely anticipated by urologists, which was confirmed by the excessive curiosity within the iTind gadget on the Olympus sales space on the 2022 AUA assembly,” mentioned Vanessa Malka, Executive Director and iTind Commercial Head for Olympus Corporation. “The outcomes show that the iTind process is a substitute for present BPH therapies. It contributes to optimistic affected person outcomes as a result of it’s sturdy and, as a short lived implant, doesn’t preclude future remedy choices.”
BPH is a noncancerous enlargement of the prostate and one of the crucial widespread ailments in growing old males. BPH impacts roughly 50% of males between the ages of 51 and 60 and as much as 90% of males over the age of 80.2 BPH signs embrace frequent urination with a way of urgency and a weak urinary stream, and extreme urination at night time.3 Suffered over time, these signs can have a adverse impression on general high quality of life.4 With most males going through BPH of their lifetimes, there’s a want for extra minimally invasive remedy choices past medication and surgical procedure.
The iTind process entails the position of a short lived nitinol gadget that reshapes the prostatic urethra with out burning or reducing out tissue. The gadget stays in place for 5 to seven days whereas the affected person is at residence. Clinical trials have demonstrated that, upon removing, sufferers expertise instant aid of their signs with none impact on their sexual perform.5
As with any medical process, implantation of the iTind gadget comes with the potential of unwanted effects, together with pelvic discomfort, blood in urine, painful or pressing urination. In uncommon instances, the iTind gadget might trigger urinary tract an infection or a sudden issue to urinate.
The worldwide multicenter potential research was funded by Medi-Tate, an entirely owned subsidiary of Olympus Corporation. Publication of the research outcomes is pending evaluate.
More details about the iTind process within the U.S. is obtainable at BPHTherapy.com/iTind and within the EMEA area at olympus-europa.com/medical/en/Products-and-Solutions/Products/Product/iTind.html.
A number one medical expertise firm, Olympus makes use of revolutionary capabilities in medical expertise, therapeutic intervention, and precision manufacturing to assist healthcare professionals ship diagnostic, therapeutic, and minimally invasive procedures to enhance scientific outcomes, scale back general prices, and improve the standard of life for sufferers. Olympus’ portfolio contains endoscopes, laparoscopes, and video imaging programs, in addition to surgical vitality gadgets, system integration options, medical companies, and a variety of endotherapy devices. For extra data, go to Olympus-Global.com.
1 Amparore D, De Cillis S, Fiori C, Kadner G, Schulman C, Porpiglia F. Long time period Follow Up of an International Multicenter Prospective Study in Application of Temporary Implantable Nitinol Device (iTind) in Men with Lower Urinary Tract Symptoms for BPH. Urology. 2022;207(5):e1307. doi.org/10.1097/JU.0000000000002669.06
2 What is Benign Prostatic Hyperplasia (BPH)? UrologyWell being.org. https://www.urologyhealth.org/urology-a-z/b/benign-prostatic-hyperplasia-(bph). Updated September 2021. Accessed March 8, 2022.
3 Benign prostatic hyperplasia (BPH). Urology Care Foundation. Accessed November 12, 2021. https://www.urologyhealth.org/urology-a-z/b/benign-prostatic-hyperplasia-(bph)
4 Alcaraz A, Carballido-Rodríguez J, Unda-Urzaiz M, et al. Quality of life in sufferers with decrease urinary tract signs related to BPH: change over time in real-life observe based on treatment–the QUALIPROST research. Int Urol Nephrol. 2016;48(5):645-656. doi:10.1007/s11255-015-1206-7
5 Chughtai B, Elterman D, Shore N, et al. The iTind Temporarily Implanted Nitinol Device for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Multicenter, Randomized, Controlled Trial [published online ahead of print, 2020 Dec 26]. Urology. 2020;S0090-4295(20)31520-X. DOI: 10.1016/j.urology.2020.12.022
SOURCE Olympus Corporation
#Study #Results #Show #Longterm #Efficacy #iTind #Procedure